Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) EPS (Basic): 2009-2024

Historic EPS (Basic) for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$3.83.

  • Anika Therapeutics' EPS (Basic) rose 89.16% to -$0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 65.05%. This contributed to the annual value of -$3.83 for FY2024, which is 32.09% up from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' EPS (Basic) is -$3.83, which was up 32.09% from -$5.64 recorded in FY2023.
  • Over the past 5 years, Anika Therapeutics' EPS (Basic) peaked at $0.29 during FY2021, and registered a low of -$5.64 during FY2023.
  • Moreover, its 3-year median value for EPS (Basic) was -$3.83 (2024), whereas its average is -$3.50.
  • In the last 5 years, Anika Therapeutics' EPS (Basic) soared by 117.16% in 2021 and then slumped by 452.94% in 2023.
  • Over the past 5 years, Anika Therapeutics' EPS (Basic) (Yearly) stood at -$1.69 in 2020, then soared by 117.16% to $0.29 in 2021, then plummeted by 451.72% to -$1.02 in 2022, then crashed by 452.94% to -$5.64 in 2023, then spiked by 32.09% to -$3.83 in 2024.